Astrocytoma Treatments

Find Astrocytoma Treatments

Brand Name

Gliadel

Generic Name

Carmustine

View Brand Information

FDA approval date: December 13, 2012

Classification: Alkylating Drug

Form: Kit, Wafer

What is Gliadel (Carmustine)?

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation and recurrent glioblastoma as an adjunct to surgery

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma

Enrollment Status: Recruiting

Publish Date: June 16, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate the safety and efficacy of tebentafusp-tebn in combination with hepatic IE in patients with a low to...

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Enrollment Status: Recruiting

Publish Date: June 10, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an a...

A Single-arm, Single-center, Open-label Clinical Study on the Efficacy and Safety of CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

Enrollment Status: Recruiting

Publish Date: May 13, 2026

Intervention Type: Biological

Study Phase: Phase 2

Summary: This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.

View All Clinical Trials

Related Latest Advances

Susceptibility to seizures and expression of fibroblast growth factor 17 in rats with Cortical dysplasia and its effects on the hippocampal neurons

Journal: Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Published: May 06, 2026

Pharmacovigilance of carmustine: distinct neurotoxic and systemic safety signals identified in FAERS.

Journal: BMC cancer

Published: April 25, 2026

Correction: Efficacy of local convection enhanced delivery of chemotherapy using an intracerebral osmotic pump in a rat model of glioblastoma.

Journal: Frontiers in oncology

Published: March 11, 2026

View All Latest Advances

Brand Information

Gliadel (carmustine)

1INDICATIONS AND USAGE

GLIADEL Wafer is indicated for the treatment of patients with:

newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and
recurrent glioblastoma as an adjunct to surgery.

2DOSAGE FORMS AND STRENGTHS

GLIADEL Wafer is an off-white to pale yellow round wafer. Each GLIADEL Wafer contains 7.7 mg of carmustine.

3CONTRAINDICATIONS

None.

4ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

Seizures
Intracranial Hypertension
Impaired Neurosurgical Wound Healing
Meningitis

4.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

5DESCRIPTION

GLIADEL Wafer is an implant for intracranial use, containing carmustine, a nitrosourea alkylating agent, and polifeprosan, a biodegradable copolymer used to control the release of carmustine. It is a sterile, off-white to pale yellow wafer approximately 1.45 cm in diameter and 1 mm thick. Each wafer contains 7.7 mg of carmustine [1, 3-bis (2-chloroethyl)-1-nitrosourea, or BCNU] and 192.3 mg of a biodegradable polyanhydride copolymer. The copolymer, polifeprosan 20, consists of poly [bis (p-carboxyphenoxy)] propane and sebacic acid in a 20:80 molar ratio. Carmustine is homogeneously distributed in the copolymer matrix.

The structural formula for polifeprosan 20 is:

The structural formula for carmustine is:

6REFERENCES

"OSHA Hazardous Drugs".

7HOW SUPPLIED/STORAGE AND HANDLING

GLIADEL Wafer is supplied in a single dose treatment box containing eight individually pouched wafers. Each wafer contains 7.7 mg of carmustine and is packaged in two aluminum foil laminate pouches. The inner pouch is sterile and is designed to maintain product sterility and protect the product from moisture. The outer pouch is a peelable overwrap. The outside surface of the outer pouch is not sterile.

NDC for single dose treatment box: 24338-050-08

8PRINCIPAL DISPLAY PANEL - 8 Wafer Box

NDC 24338-050-08

GLIADEL
(carmustine implant)

7.7 mg carmustine/wafer

For intracranial use.

Each sterile wafer contains

Contents:

Store at or below -20°C (-4°F).
Rx only

Warning:Cytotoxic agent
See package insert for full prescribing information.
Keep out of the reach of children.

Azurity PHARMACEUTICALS, Inc.